Online inquiry

IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13526MR)

This product GTTS-WQ13526MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MCAM gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_006500.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4162
UniProt ID P43121
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13526MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5673MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ15951MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ9523MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ5834MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ3726MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ3387MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ13664MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ1327MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-700
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW